TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29858517
Drug: Intraneural injections
Normalized name: bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraneural injections
Study: 23666832
Drug: Directly observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly observed home-based daily iron therapy (DOHBIT)
Study: 23666832
Drug: Unsupervised self-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised self-treatment at home
Study: 22010015
Drug: Dulanermin 8
Normalized name: Dulanermin
DrugBank: Dulanermin (DB12349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulanermin 8 mg/kg for 5 days with paclitaxel and carboplatin (arm 2)
Study: 22010015
Drug: Dulanermin 8
Normalized name: Dulanermin
DrugBank: Dulanermin (DB12349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulanermin 8 mg/kg for 5 days with paclitaxel, carboplatin, and bevacizumab (arm 4)
Study: 22010015
Drug: Dulanermin 20
Normalized name: Dulanermin
DrugBank: Dulanermin (DB12349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulanermin 20 mg/kg for 2 days with paclitaxel, carboplatin, and bevacizumab (arm 5)
Study: 12844472
Drug: Vitamin-mineral drug
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-mineral drug combination containing dimethylaminoethanol (DMAE)
Study: 7890006
Drug: Gabexate mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesilate (Gab) infusion after liver resection
Study: 2778501
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg daily oral sobrerol for 7 days
Study: 31084488
Drug: Triamcinolone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone (40 mg) and lidocaine (1.5 mL) injection into the glenohumeral joint 8 weeks after surgery (group 1)
Study: 31084488
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection (group 2)
Study: 28218420
Drug: Aspirin and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and/or folic acid treatment
Study: 19005755
Drug: Omeprazole, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, amoxicillin, metronidazole, and bismuth subcitrate (Group A)
Study: 19005755
Drug: Omeprazole, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, amoxicillin, and clarithromycin (Group B)
Study: 12199276
Drug: Pilocarpine (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (15-30 mg/day)
Study: 7656926
Drug: Thyroid replacement
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid replacement therapy (TRT)
Study: 2486951
Drug: Nimesulide 100
Normalized name: nimesulide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 100 mg every 12 hrs for 5 days
Study: 31836203
Drug: Daily disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily disposable soft contact lenses (Dailies Total 1, Dailies Aqua Comfort, TruEye, Biotrue Oneday)
Study: 21110014
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (RPZ) 20 mg
Study: 21110014
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (RPZ) 10 mg
Study: 21110014
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (RPZ) high-dose
Study: 21110014
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabeprazole (RPZ) low-, middle-, and high-dose
Study: 14564194
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of dialysis
Study: 14564194
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of dialysis
Study: 10027500
Drug: Slow-release nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release nifedipine (calcium channel blocker)
Study: 27575450
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg sugammadex
Study: 24447651
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg sugammadex
Study: 29465480
Drug: Trivalent influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent influenza vaccine
Study: 3307518
Drug: Ketorolac 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 1.5 mg/hour
Study: 3307518
Drug: Ketorolac 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 3.0 mg/hour
Study: 14990633
Drug: Gefitinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (500 mg/d and 250 mg/d)
Study: 24940526
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy
Study: 7539182
Drug: Selective alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective alpha 1 blockers
Study: 19815265
Drug: Silodosin 8
Normalized name: silodosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 8 mg once daily with breakfast (continuing treatment)
Study: 19815265
Drug: Silodosin (de
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin (de novo treatment)
Study: 4083300
Drug: 24-hour sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour sustained-release theophylline formulation, Uniphyl
Study: 4083300
Drug: Twice-daily compound,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily compound, Theo-Dur
Study: 25996838
Drug: HBvaxPRO® (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBvaxPRO® (10 μg)
Study: 16740846
Drug: Stimulant (dexamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant (dexamphetamine or methylphenidate)
Study: 16740846
Drug: Stimulant (post-trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant (post-trial management)
Study: 8204943
Drug: Droloxifene 100
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 100 mg/day
Study: 3402181
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of metoclopramide (loading dose of 3 mg/kg followed by 0.5 mg/kg/hr for 12 hours)
Study: 3402181
Drug: Bolus doses
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus doses of metoclopramide (2 mg/kg added to each bolus dose)
Study: 3402181
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of metoclopramide (placebo of 5% dextrose injection)
Study: 3402181
Drug: Bolus doses
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus doses of metoclopramide (placebo of 5% dextrose injection)
Study: 29658353
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (5‐mg intravenous injection, administered 1 week postoperatively)
Study: 29658353
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered 1 week postoperatively)
Study: 6837864
Drug: Depilatory cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depilatory cream
Study: 18435231
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education by health visitor, including dental health advice, toothbrush and toothpaste with 440 ppm fluoride, provided during home visits at ages 8 months and 20 months.
Study: 16586358
Drug: Trivalent baculovirus-expressed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent baculovirus-expressed HA vaccine at 45 microg
Study: 27082828
Drug: Methylphenidate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate treatment
Study: 1330019
Drug: Cholera toxin
Normalized name: Cholera toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera toxin (15 micrograms or 25 micrograms) administered into a 'closed' jejunal segment
Study: 1330019
Drug: Cholera toxin
Normalized name: Cholera toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera toxin administered by mouth with sodium bicarbonate
Study: 27598679
Drug: Transvenous neurostimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvenous neurostimulation (treatment group)
Study: 24247616
Drug: Varespladib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varespladib (500 mg daily for 16 weeks)
Study: 11487536
Drug: Natalizumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab (3 mg/kg infusion)
Study: 31994643
Drug: 5% naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% naproxen patches
Study: 17897470
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches
Study: 24996984
Drug: BAL-directed therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAL-directed therapy
Study: 18633127
Drug: Allopurinol 600
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 600 mg/day (stage 2)
Study: 18633127
Drug: Benzbromarone 200
Normalized name: benzbromarone
DrugBank: Benzbromarone (DB12319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzbromarone 200 mg/day (stage 2)
Study: 17353072
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (Lactobacillus rhamnosus GG and LC705, Bifidobacterium breve 99 and Propionibacterium freudenreichii JS)
Study: 29101841
Drug: One Session
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Session Treatment (OST)
Study: 28145413
Drug: Lovaza (omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovaza (omega-3 preparation)
Study: 20043831
Drug: Daily activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily activity monitoring and distance counselling (12 months)
Study: 17295588
Drug: Nicotine (0.60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (0.60 mg)
Study: 17295588
Drug: Nicotine (0.60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (0.60 mg) and Expectancy
Study: 11506058
Drug: 3.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 g/day phytosterols
Study: 11506058
Drug: 6.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.0 g/day phytosterols
Study: 11506058
Drug: 9.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.0 g/day phytosterols
Study: 11506058
Drug: 0.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0 g/day phytosterols (control)
Study: 27060991
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (CT) with silodosin at 8 mg/day and propiverine at 20 mg/day
Study: 27060991
Drug: α1-blocker monotherapy
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: α1-blocker monotherapy (MT) with silodosin at 8 mg/day
Study: 25702095
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg tranexamic acid (TXA) in 100 mL normal saline solution
Study: 20048210
Drug: varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: varenicline (1 mg twice daily)
Study: 1611645
Drug: Amoxicillin/clavulanate (500/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (500/125 mg thrice daily)
Study: 1505371
Drug: Loracarbef (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef (400 mg twice daily)
Study: 20718545
Drug: Daily prayer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily prayer for 4 weeks
Study: 11923036
Drug: Each 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 100 ng/ml increase in sICAM‐1 concentration
Study: 8197035
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine 10 mg
Study: 2656777
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate 10 mg
Study: 28103714
Drug: Gaze‐contingent music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaze‐contingent music reward therapy
Study: 19801040
Drug: PM101 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM101 (50 mg/ml, bolus push)
Study: 19801040
Drug: Standard loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard loading dose of AIV (150 mg, infused at 1.5 mg/ml over 10 minutes)
Study: 19801040
Drug: Rapid loading
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid loading dose of AIV (150 mg, infused undiluted at 50 mg/ml over 15 seconds)
Study: 16412749
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and low molecular weight heparin treatment in women with APS
Study: 31270774
Drug: Active therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active therapy
Study: 8203857
Drug: Standard antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antimicrobial prophylaxis (400 mg of norfloxacin orally three times a day, 200 mg of fluconazole orally once a day, and 5 mg of acyclovir per kg of body weight i.v. q12h) without gram-positive prophylaxis.
Study: 30805949
Drug: NGM282 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGM282 1 mg
Study: 29717197
Drug: NGM282 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGM282 6 mg
Study: 29717197
Drug: NGM282 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGM282 (1 mg and 6 mg)
Study: 24039194
Drug: 12 hours
Normalized name: PATCH, TRANSDERMAL 12 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 hours of intravenous prehydration before HDMTX infusion
Study: 24039194
Drug: 4 hours
Normalized name: PATCH, TRANSDERMAL 24 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 hours of intravenous prehydration before HDMTX infusion
Study: 22743321
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg L and 1 mg Z supplementation
Study: 19078818
Drug: Subcutaneous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous lidocaine (0.5 ml of 2% lidocaine 2 min before arterial puncture)
Study: 10517342
Drug: Modified radical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified radical mastectomy or breast conservation treatment
Study: 7739851
Drug: 0.2 g
Normalized name: methionine 0.2 gram ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g caffeine administered orally
Study: 7739851
Drug: Caffeine elimination
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine elimination measured at 12 hours post-administration
Study: 12700955
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 10 mg once daily
Study: 340131
Drug: Tinidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (2 g once daily for 3 consecutive days)
Study: 340131
Drug: Metronidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (2 g once daily for 3 consecutive days)
Study: 30198451
Drug: Immersive virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersive virtual reality plus morphine
Study: 24755130
Drug: Morphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine alone
Study: 14675406
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous methotrexate (HDMTX) (6-8 g/m2) with intrathecal methotrexate (ITMTX)
Study: 11703217
Drug: Problem-based health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-based health education program (n=18), multidisciplinary approach, cognitive behavioral therapy exercises, 7 sessions over 5 months
Study: 28691866
Drug: Venetoclax 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax 600 mg multiple ascending dose
Study: 28691866
Drug: Venetoclax (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (various doses)
Study: 24000874
Drug: Continuous or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous or intermittent users of other antihypertensive drugs
Study: 24000874
Drug: Never‐users of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Never‐users of antihypertensive drugs
Study: 20621401
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 75 mg intramuscularly
Study: 17081832
Drug: Cocoa flavanol-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanol-enriched snack bar containing 1.5 g phytosterol
Study: 3282531
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral pimobendane (UD-CG 115)
Study: 19629514
Drug: Rheopheresis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheopheresis treatment (10 treatments within 17 weeks)
Study: 16202012
Drug: Rheopheresis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheopheresis treatment
Study: 26638037
Drug: Weekly follow‐up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly follow‐up phone calls in addition to scripted diagnosis and inpatient psychiatry consultation (n=15)
Study: 25546486
Drug: Delayed VT
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed VT therapy ICD programming (arm C)
Study: 25546486
Drug: First inappropriate
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First inappropriate ICD therapy
Study: 25546486
Drug: First appropriate
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First appropriate ICD therapy
Study: 17023234
Drug: Once-Daily Controlled-Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-Daily Controlled-Release Carvedilol CR
Study: 17023234
Drug: Twice-Daily Immediate-Release
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-Daily Immediate-Release Carvedilol IR
Study: 19242664
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg twice weekly)
Study: 6381314
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (b.i.d. and q.i.d.)
Study: 29934701
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (diosmin in combination with hesperidin, diosmetin, isoroifolin, and linarin in purified micronized fraction)
Study: 26910697
Drug: Postoperative arnica
Normalized name: ARNICA
DrugBank: Arnica montana flower (DB14343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative arnica cream treatment (Group 1, n = 36)
Study: 26910697
Drug: Postoperative mucopolysaccharide
Normalized name: sulfated mucopolysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative mucopolysaccharide polysulfate cream treatment (Group 2, n = 36)
Study: 24281981
Drug: Carbetocin (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (initial dose 10 μg, increments/decrements of 5 μg)
Study: 20357486
Drug: Dpg-Pol extracts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dpg-Pol extracts (100 HEPL/ml) administered with 6 up-dosing and monthly maintenance injections for 1 year
Study: 18478481
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD, 1.5 g NS day (‐1))
Study: 18478481
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD, 3.0 g NS day (‐1))
Study: 31973700
Drug: Levobupivacaine (L)
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levobupivacaine (L)
Study: 8660169
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment (specific agents not detailed)
Study: 2874663
Drug: Celiprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (200 mg daily)
Study: 11561116
Drug: Nifedipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (40 mg daily)
Study: 27419856
Drug: Group medical
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group medical visits (GMVs) incorporating CAM therapies (mindfulness techniques, movement, guided imagery, relaxation training, yoga, qigong, t'ai chi)
Study: 24144212
Drug: 10 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg/day hydroxyurea (HU)
Study: 24144212
Drug: 20 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg/day hydroxyurea (HU)
Study: 8636753
Drug: Toremifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (60 mg orally per day for 3 years)
Study: 8636753
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg orally per day for 3 years)
Study: 3863624
Drug: PGE2 gel
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 gel (0.5 mg dose)
Study: 15618687
Drug: Cefdinir 200
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 200 mg alone (Study 1)
Study: 27933399
Drug: Nurse-guided clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-guided clinical decision support system for rehydration treatment
Study: 22256652
Drug: Infantile Tuina
Normalized name: Dolofin Infantil
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infantile Tuina treatment (tonifying Pijing, clarifying Dachangjing, Tuina on Lanmen, Qi, Fu Shangqijiegu, Guiwei, Zusanli (ST 36), Banmen, Sanguan)
Study: 28482621
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no therapy)
Study: 22538270
Drug: Gemfibrozil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (600 mg b.i.d)
Study: 22538270
Drug: Brivaracetam (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam (150 mg) alone
Study: 19969437
Drug: Pimozide formulation
Normalized name: Pimozide
DrugBank: Pimozide (DB01100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimozide formulation 1
Study: 19969437
Drug: Pimozide formulation
Normalized name: Pimozide
DrugBank: Pimozide (DB01100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pimozide formulation 2
Study: 18768019
Drug: Oral-B Sensitive
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Sensitive Advantage (OBSA)
Study: 1804650
Drug: AS-4370 5
Normalized name: remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AS-4370 5 mg